RESUMO
Bacterial lung infections, particularly with methicillin-resistant Staphylococcus aureus (MRSA), increase mortality following influenza infection, but the mechanisms remain unclear. Here we show that expression of TLR9, a microbial DNA sensor, is increased in murine lung macrophages, dendritic cells, CD8+ T cells and epithelial cells post-influenza infection. TLR9-/- mice did not show differences in handling influenza nor MRSA infection alone. However, TLR9-/- mice have improved survival and bacterial clearance in the lung post-influenza and MRSA dual infection, with no difference in viral load during dual infection. We demonstrate that TLR9 is upregulated on macrophages even when they are not themselves infected, suggesting that TLR9 upregulation is related to soluble mediators. We rule out a role for elevations in interferon-γ (IFNγ) in mediating the beneficial MRSA clearance in TLR9-/- mice. While macrophages from WT and TLR9-/- mice show similar phagocytosis and bacterial killing to MRSA alone, following influenza infection, there is a marked upregulation of scavenger receptor A and MRSA phagocytosis as well as inducible nitric oxide synthase (Inos) and improved bacterial killing that is specific to TLR9-deficient cells. Bone marrow transplant chimera experiments and in vitro experiments using TLR9 antagonists suggest TLR9 expression on non-hematopoietic cells, rather than the macrophages themselves, is important for regulating myeloid cell function. Interestingly, improved bacterial clearance post-dual infection was restricted to MRSA, as there was no difference in the clearance of Streptococcus pneumoniae. Taken together these data show a surprising inhibitory role for TLR9 signaling in mediating clearance of MRSA that manifests following influenza infection.
Assuntos
Staphylococcus aureus Resistente à Meticilina/imunologia , Staphylococcus aureus Resistente à Meticilina/metabolismo , Receptor Toll-Like 9/metabolismo , Animais , Humanos , Influenza Humana/imunologia , Pulmão/imunologia , Macrófagos , Macrófagos Alveolares/imunologia , Macrófagos Alveolares/patologia , Staphylococcus aureus Resistente à Meticilina/patogenicidade , Camundongos , Camundongos Endogâmicos BALB C , Camundongos Knockout , Infecções por Orthomyxoviridae/imunologia , Fagocitose , Infecções Estafilocócicas/microbiologia , Staphylococcus aureus/imunologia , Receptor Toll-Like 9/genéticaRESUMO
Human metapneumovirus (hMPV) is a recently described paramyxovirus that causes lower respiratory infections in children and adults worldwide. The hMPV fusion (F) protein is a membrane-anchored glycoprotein and major protective antigen. All hMPV F protein sequences determined to date contain an Arg-Gly-Asp (RGD) sequence, suggesting that F engages RGD-binding integrins to mediate cell entry. The divalent cation chelator EDTA, which disrupts heterodimeric integrin interactions, inhibits infectivity of hMPV but not the closely related respiratory syncytial virus (RSV), which lacks an RGD motif. Function-blocking antibodies specific for alphavbeta1 integrin inhibit infectivity of hMPV but not RSV. Transfection of nonpermissive cells with alphav or beta1 cDNAs confers hMPV infectivity, whereas reduction of alphav and beta1 integrin expression by siRNA inhibits hMPV infection. Recombinant hMPV F protein binds to cells, whereas Arg-Gly-Glu (RGE)-mutant F protein does not. These data suggest that alphavbeta1 integrin is a functional receptor for hMPV.
Assuntos
Metapneumovirus/patogenicidade , Receptores de Vitronectina/fisiologia , Virulência/fisiologia , Animais , Anticorpos Antivirais/imunologia , Humanos , Metapneumovirus/imunologia , RNA Interferente Pequeno , Receptores de Vitronectina/imunologia , Suínos , Transfecção , Proteínas Virais de Fusão/química , Proteínas Virais de Fusão/fisiologiaRESUMO
Human metapneumovirus (hMPV) is a recently discovered paramyxovirus that causes upper and lower respiratory tract infections in infants, the elderly, and immunocompromised individuals worldwide. Here, we developed Venezuelan equine encephalitis virus replicon particles (VRPs) encoding hMPV fusion (F) or attachment (G) glycoproteins and evaluated the immunogenicity and protective efficacy of these vaccine candidates in mice and cotton rats. VRPs encoding hMPV F protein, when administered intranasally, induced F-specific virus-neutralizing antibodies in serum and immunoglobulin A (IgA) antibodies in secretions at the respiratory mucosa. Challenge virus replication was reduced significantly in both the upper and lower respiratory tracts following intranasal hMPV challenge in these animals. However, vaccination with hMPV G protein VRPs did not induce neutralizing antibodies or protect animals from hMPV challenge. Close examination of the histopathology of the lungs of VRP-MPV F-vaccinated animals following hMPV challenge revealed no enhancement of inflammation or mucus production. Aberrant cytokine gene expression was not detected in these animals. Together, these results represent an important first step toward the use of VRPs encoding hMPV F proteins as a prophylactic vaccine for hMPV.
Assuntos
Metapneumovirus/imunologia , Infecções por Paramyxoviridae/prevenção & controle , Vacinas Virais/imunologia , Administração Intranasal , Animais , Anticorpos Antivirais/sangue , Linhagem Celular , Vírus da Encefalite Equina Venezuelana/genética , Imunoglobulina A/análise , Imunoglobulina G/sangue , Pulmão/patologia , Pulmão/virologia , Macaca mulatta , Camundongos , Camundongos Endogâmicos DBA , Mucosa/imunologia , Testes de Neutralização , Ratos , Sistema Respiratório/virologia , Sigmodontinae , Proteínas Estruturais Virais/genética , Proteínas Estruturais Virais/imunologia , Vacinas Virais/administração & dosagemRESUMO
There is only limited knowledge on the burden of disease due to both new (HCoV-NL63 and HKU-1) and previously discovered coronaviruses (OC43 and 229E) in children. Respiratory specimens and clinical data were prospectively collected in an active, population-based surveillance study over a 2-year period from children aged <5 years hospitalized with acute respiratory symptoms or fever. These samples were retrospectively tested by real-time RT-PCR for HCoV-NL63, HKU1, OC43, and 229E. Human coronaviruses (HCoVs) were identified in 2.2% of study children <2 years of age. Rates of HCoV-associated hospitalization per 10,000 were 10.2 (95% CI 4.3, 17.6), 4.2 (95% CI 1.9, 6.9), and 0 (95% CI 0, 3.7) in children aged <6 months, 6-23 months, and 24-59 months, respectively. Coronaviruses were identified in a modest number of hospitalized children.
Assuntos
Infecções por Coronavirus/epidemiologia , Coronavirus/classificação , Coronavirus/isolamento & purificação , Hospitalização/estatística & dados numéricos , Infecções Respiratórias/epidemiologia , Doença Aguda , Pré-Escolar , Coronavirus/genética , Coronavirus Humano 229E/classificação , Coronavirus Humano 229E/genética , Coronavirus Humano 229E/isolamento & purificação , Infecções por Coronavirus/virologia , Coronavirus Humano OC43/classificação , Coronavirus Humano OC43/genética , Coronavirus Humano OC43/isolamento & purificação , Feminino , Humanos , Incidência , Lactente , Recém-Nascido , Masculino , Vigilância da População , Sistema Respiratório/virologia , Infecções Respiratórias/virologiaRESUMO
BACKGROUND: The epidemiology of human coronaviruses (HCoVs) has not been established using reverse transcription polymerase chain reaction techniques in a specimen collection that spans decades. METHODS: We used real-time RT-PCR for 3 HCoVs, HCoV 229E, OC43, and NL63, to test nasal wash specimens that had been obtained from a cohort of children <5 years of age with upper or lower respiratory infection (URI, LRI) who were comprehensively followed during the period from 1977 to 2001. Prospectively collected clinical data and archival samples were analyzed. RESULTS: HCoV was detected in 92/1854 (5.0%) of available samples with no known viral etiology of which 9% were 229E, 59% OC43, and 33% NL63. This represented 10/119 (8.4%) of LRI samples and 82/1735 (4.7%) of URI samples. HCoV was not detected every year, but occurred episodically. The recently described HCoV-NL63 was detected as early as 1981. HCoV was associated with 11.4 LRI episodes/1000 child-years <5 years of age (all in children <2 years of age) and 67.3 URI episodes/1000 child-years <5 years of age. CONCLUSIONS: HCoV-NL63 and OC43 are associated with a significant proportion of LRI in children less than 2 years of age and a substantial number of medically attended URI episodes.
Assuntos
Infecções por Coronavirus/epidemiologia , Coronavirus/isolamento & purificação , Infecções Respiratórias/epidemiologia , Pré-Escolar , Coronavirus/genética , Infecções por Coronavirus/virologia , Feminino , Humanos , Incidência , Lactente , Modelos Logísticos , Masculino , Estudos Prospectivos , Sistema Respiratório/virologia , Infecções Respiratórias/virologia , Reação em Cadeia da Polimerase Via Transcriptase Reversa/métodosRESUMO
INTRODUCTION: Post influenza pneumonia is a leading cause of mortality and morbidity, with mortality rates approaching 60% when bacterial infections are secondary to multi-drug resistant (MDR) pathogens. Staphylococcus aureus, in particular community acquired MRSA (cMRSA), has emerged as a leading cause of post influenza pneumonia. HYPOTHESIS: Linezolid (LZD) prevents acute lung injury in murine model of post influenza bacterial pneumonia. METHODS: Mice were infected with HINI strain of influenza and then challenged with cMRSA at day 7, treated with antibiotics (LZD or Vanco) or vehicle 6 hours post bacterial challenge and lungs and bronchoalveolar lavage fluid (BAL) harvested at 24 hours for bacterial clearance, inflammatory cell influx, cytokine/chemokine analysis and assessment of lung injury. RESULTS: Mice treated with LZD or Vanco had lower bacterial burden in the lung and no systemic dissemination, as compared to the control (no antibiotic) group at 24 hours post bacterial challenge. As compared to animals receiving Vanco, LZD group had significantly lower numbers of neutrophils in the BAL (9×10(3) vs. 2.3×10(4), p < 0.01), which was associated with reduced levels of chemotactic chemokines and inflammatory cytokines KC, MIP-2, IFN-γ, TNF-α and IL-1ß in the BAL. Interestingly, LZD treatment also protected mice from lung injury, as assessed by albumin concentration in the BAL post treatment with H1N1 and cMRSA when compared to vanco treatment. Moreover, treatment with LZD was associated with significantly lower levels of PVL toxin in lungs. CONCLUSION: Linezolid has unique immunomodulatory effects on host inflammatory response and lung injury in a murine model of post-viral cMRSA pneumonia.
Assuntos
Acetamidas/administração & dosagem , Influenza Humana/tratamento farmacológico , Staphylococcus aureus Resistente à Meticilina/efeitos dos fármacos , Oxazolidinonas/administração & dosagem , Pneumonia Bacteriana/tratamento farmacológico , Animais , Humanos , Imunomodulação , Vírus da Influenza A Subtipo H1N1/efeitos dos fármacos , Vírus da Influenza A Subtipo H1N1/patogenicidade , Influenza Humana/complicações , Linezolida , Staphylococcus aureus Resistente à Meticilina/patogenicidade , Camundongos , Pneumonia Bacteriana/complicações , Pneumonia Bacteriana/microbiologia , Infecções Estafilocócicas/tratamento farmacológicoRESUMO
Human metapneumovirus (HMPV) expresses the major surface glycoproteins F and G. We evaluated the protective efficacy of immunization with G. We generated a recombinant form of G ectodomain (GDeltaTM) that was secreted from mammalian cells and purified by affinity chromatography. We tested the immunogenicity of GDeltaTM in cotton rats. Animals were immunized with PBS, GDeltaTM alone or adjuvanted, or were infected once with HMPV, and challenged with live HMPV at 28 days. Animals vaccinated with adjuvanted and non-adjuvanted GDeltaTM developed high levels of serum antibodies to both recombinant and native G protein; however, vaccinated animals did not develop neutralizing antibodies and were not protected against virus challenge. Unlike the analogous non-fusion glycoproteins of other human paramyxoviruses, HMPV G does not appear to be a protective antigen. This represents an unusual feature of HMPV.
Assuntos
Glicoproteínas/imunologia , Metapneumovirus/imunologia , Infecções por Paramyxoviridae/imunologia , Proteínas Virais/imunologia , Animais , Anticorpos Neutralizantes/sangue , Anticorpos Antivirais/sangue , Citocinas/imunologia , Glicosilação , Cobaias , Pulmão/patologia , Pulmão/virologia , Infecções por Paramyxoviridae/prevenção & controle , Ratos , Proteínas Recombinantes/imunologia , VacinaçãoRESUMO
The performance of a diagnostic microarray (the MChip assay) for influenza was compared in a blind study to that of viral culture, reverse transcription (RT)-PCR, and the QuickVue Influenza A+B test. The patient sample data set was composed of 102 respiratory secretion specimens collected between 29 December 2005 and 2 February 2006 at Scott & White Hospital and Clinic in Temple, Texas. Samples were collected from a wide range of age groups by using direct collection, nasal/nasopharyngeal swabs, or nasopharyngeal aspiration. Viral culture and the QuickVue assay were performed at the Texas site at the time of collection. Aliquots for each sample, identified only by study numbers, were provided to the University of Colorado and Vanderbilt University teams for blinded analysis. When referenced to viral culture, the MChip exhibited a clinical sensitivity of 98% and a clinical specificity of 98%. When referenced to RT-PCR, the MChip assay exhibited a clinical sensitivity of 92% and a clinical specificity of 98%. While the MChip assay currently requires 7 to 8 h to complete the analysis, a significant advantage of the test for influenza virus-positive samples is simultaneous detection and full subtype identification for the two subtypes currently circulating in humans (A/H3N2 and A/H1N1) and avian (A/H5N1) viruses.